Melanoma Therapeutics Market Analysis By Therapy, By Drugs (Opdivo, Yervoy, Mekinist+Tafinlar, Keytruda, Cotellic, Zelboraf, Imlygic, Generics), And Segment Forecasts, 2018 - 2025

Table of Contents

Chapter 1 Research Methodology
1.1 Country-wise Market: Base Estimates
1.1.1 Global market: CAGR calculation
1.1.2 Region-based segment share calculation
1.2 Research Scope & Assumptions
1.3 List of Data Sources
Chapter 2 Executive Summary
2.1 Market Snapshot
Chapter 3 Melanoma Therapeutics Market Variables, Trends & Scope
3.1 Market Segmentation & Scope
3.2 Market Driver Analysis
3.2.1 Increasing incidence of skin-related disorders such as skin cancer and skin allergies
3.2.2 Increasing initiatives from public and private organizations
3.2.3 Presence of strong emerging pipeline
3.3 Market Restraint Analysis
3.3.1 High cost associated with various therapies
3.4 Penetration & Growth Prospect Mapping
3.5 Melanoma Therapeutics - SWOT Analysis, by Factor (Political & Legal, Economic and Technological)
3.6 Market Analysis - Porter’s
Chapter 4 Melanoma Therapeutics Market: Therapy Estimates & Trend Analysis
4.1 Melanoma Therapeutics Market: Therapy Movement Analysis
4.2 Chemotherapy
4.2.1 Chemotherapy market, 2014 - 2025 (USD Million)
4.3 Immunotherapy
4.3.1 Immunotherapy market, 2014 - 2025 (USD Million)
4.4 Targeted Therapy
4.4.1 Targeted therapy market, 2014 - 2025 (USD Million)
4.5 Radiation Therapy
4.5.1 Radiation therapy market, 2014 - 2025 (USD Million)
Chapter 5 Melanoma Therapeutics Market: Drug Estimates & Trend Analysis
5.1 Melanoma Therapeutics Market: Drug Movement Analysis
5.2 Branded Drugs
5.2.1 Branded drugs market, 2014 - 2025 (USD Million)
5.2.2 Opdivo
5.2.5.1 Opdivo market, 2014 - 2025 (USD Million)
5.2.3 Yervoy
5.2.5.1 Yervoy market, 2014 - 2025 (USD Million)
5.2.4 Mekinist+Tafinlar
5.2.5.1 Mekinist+Tafinlar market, 2014 - 2025 (USD Million)
5.2.5 Keytruda
5.2.5.1 Keytruda market, 2014 - 2025 (USD Million)
5.2.6 Cotellic
5.2.5.1 Cotellic market, 2014 - 2025 (USD Million)
5.2.7 Zelboraf
5.2.5.1 Zelboraf market, 2014 - 2025 (USD Million)
5.2.8 Imlygic
5.2.5.1 Imlygic market, 2014 - 2025 (USD Million)
5.3 Generic Drugs
5.3.1 Generic drugs market, 2014 - 2025 (USD Million)
Chapter 6 Melanoma Therapeutics Market: Regional Estimates & Trend Analysis, by Therapy, and Drug
6.1 Melanoma Therapeutics Market Share by Region, 2016& 2025
6.2 North America
6.2.1 North America melanoma therapeutics market, by country, 2014 - 2025 (USD Million)
6.2.2 North America melanoma therapeutics market, by therapy, 2014 - 2025 (USD Million)
6.2.3北美黑色素瘤治疗市场,by drugs, 2014 - 2025 (USD Million)
6.2.4 U.S.
6.2.4.1 U.S. melanoma therapeutics market, by therapy, 2014 - 2025 (USD Million)
6.2.4.2 U.S. melanoma therapeutics market, by drugs, 2014 - 2025 (USD Million)
6.2.5 Canada
6.2.5.1 Canada melanoma therapeutics market, by therapy, 2014 - 2025 (USD Million)
6.2.5.2 Canada melanoma therapeutics market, by drugs, 2014 - 2025 (USD Million)
6.3 Europe
6.3.1 Europe melanoma therapeutics market, by country, 2014 - 2025 (USD Million)
6.3.2 Europe melanoma therapeutics market, by therapy, 2014 - 2025 (USD Million)
6.3.3 Europe melanoma therapeutics market, by drugs, 2014 - 2025 (USD Million)
6.3.4 U.K.
6.3.4.1 U.K. melanoma therapeutics market, by therapy, 2014 - 2025 (USD Million)
6.3.4.2 U.K. melanoma therapeutics market, by drugs, 2014 - 2025 (USD Million)
6.3.5 Germany
6.3.5.1 Germany melanoma therapeutics market, by therapy, 2014 - 2025 (USD Million)
6.3.5.2 Germany melanoma therapeutics market, by drugs, 2014 - 2025 (USD Million)
6.4 Asia Pacific
6.4.1 Asia Pacific melanoma therapeutics market, by country, 2014 - 2025 (USD Million)
6.4.2 Asia Pacific melanoma therapeutics market, by therapy, 2014 - 2025 (USD Million)
6.4.3 Asia Pacific melanoma therapeutics market, by drugs, 2014 - 2025 (USD Million)
6.4.4 Japan
6.4.4.1 Japan melanoma therapeutics market, by therapy, 2014 - 2025 (USD Million)
6.4.4.2 Japan melanoma therapeutics market, by drugs, 2014 - 2025 (USD Million)
6.4.5 China
6.4.5.1 China melanoma therapeutics market, by therapy, 2014 - 2025 (USD Million)
6.4.5.2 China melanoma therapeutics market, by drugs, 2014 - 2025 (USD Million)
6.4.6 India
6.4.6.1 India melanoma therapeutics market, by therapy, 2014 - 2025 (USD Million)
6.4.6.2 India melanoma therapeutics market, by drugs, 2014 - 2025 (USD Million)
6.5 Latin America
6.5.1 Latin America melanoma therapeutics market, by country, 2014 - 2025 (USD Million)
6.5.2 Latin America melanoma therapeutics market, by therapy, 2014 - 2025 (USD Million)
6.5.3 Latin America melanoma therapeutics market, by drugs, 2014 - 2025 (USD Million)
6.5.4 Brazil
6.5.4.1 Brazil melanoma therapeutics market, by therapy, 2014 - 2025 (USD Million)
6.5.4.2 Brazil melanoma therapeutics market, by drugs, 2014 - 2025 (USD Million)
6.5.5 Mexico
6.5.5.1 Mexico melanoma therapeutics market, by therapy, 2014 - 2025 (USD Million)
6.5.5.2 Mexico melanoma therapeutics market, by drugs, 2014 - 2025 (USD Million)
6.6 MEA
6.6.1 MEA melanoma therapeutics market, by country, 2014 - 2025 (USD Million)
6.6.2 MEA melanoma therapeutics market, by therapy, 2014 - 2025 (USD Million)
6.6.3 MEA melanoma therapeutics market, by drugs, 2014 - 2025 (USD Million)
6.6.4 South Africa
6.6.4.1 South Africa melanoma therapeutics market, by therapy, 2014 - 2025 (USD Million)
6.6.4.2 South Africa melanoma therapeutics market, by drugs, 2014 - 2025 (USD Million)
Chapter 7 Competitive Landscape
7.1 Strategy Framework
7.2 Market Participation
7.3 Company Profiles
7.3.1 AstraZeneca
7.3.1.1 Company overview
7.3.1.2 Financial performance
7.3.1.3 Strategic initiatives
7.3.2 Amgen, Inc.
7.3.2.1 Company overview
7.3.2.2 Financial performance
7.3.2.3 Product benchmarking
7.3.2.4 Strategic initiatives
7.3.3 F. Hoffman-La Roche Ltd.
7.3.3.1 Company overview
7.3.3.2 Financial performance
7.3.3.3 Product benchmarking
7.3.3.4 Strategic initiatives
7.3.4 Bristol-Myers Squibb Company
7.3.4.1 Company overview
7.3.4.2 Financial performance
7.3.4.3 Product benchmarking
7.3.4.4 Strategic initiatives
7.3.5 Novartis AG
7.3.5.1 Company overview
7.3.5.2财务业绩
7.3.5.3 Product benchmarking
7.3.5.4 Strategic initiatives
7.3.6 Merck & Co., Inc.
7.3.6.1 Company overview
7.3.6.2 Financial performance
7.3.6.3 Product benchmarking
7.3.6.4 Strategic initiatives
7.3.7 Daiichi Sankyo Company, Limited
7.3.7.1 Company overview
7.3.7.2 Financial performance
7.3.7.3 Strategic initiatives
7.3.8 AB Sciences
7.3.8.1 Company overview
7.3.8.2 Financial performance
7.3.8.3 Strategic initiatives

List of Tables

TABLE 1 Country share estimation
TABLE 2 North America melanoma therapeutics market, by therapy, 2014 - 2025 (USD million)
TABLE 3 North America melanoma therapeutics market, by dugs, 2014 - 2025 (USD million)
TABLE 4 U.S. melanoma therapeutics market, by therapy, 2014 - 2025 (USD million)
TABLE 5 U.S. melanoma therapeutics market, by dugs, 2014 - 2025 (USD million)
TABLE 6 Canada melanoma therapeutics market, by therapy, 2014 - 2025 (USD million)
TABLE 7 Canada melanoma therapeutics market, by dugs, 2014 - 2025 (USD million)
TABLE 8 Europe melanoma therapeutics market, by therapy, 2014 - 2025 (USD million)
TABLE 9 Europe melanoma therapeutics market, by dugs, 2014 - 2025 (USD million)
表10英国黑色素瘤治疗市场,由rapy, 2014 - 2025 (USD million)
TABLE 11 U.K. melanoma therapeutics market, by dugs, 2014 - 2025 (USD million)
TABLE 12 Germany melanoma therapeutics market, by therapy, 2014 - 2025 (USD million)
表13德国黑色素瘤治疗市场dugs, 2014 - 2025 (USD million)
TABLE 14 Asia Pacific melanoma therapeutics market, by therapy, 2014 - 2025 (USD million)
TABLE 15 Asia Pacific melanoma therapeutics market, by dugs, 2014 - 2025 (USD million)
TABLE 16 Japan melanoma therapeutics market, by therapy, 2014 - 2025 (USD million)
TABLE 17 Japan melanoma therapeutics market, by dugs, 2014 - 2025 (USD million)
TABLE 18 China melanoma therapeutics market, by therapy, 2014 - 2025 (USD million)
TABLE 19 China melanoma therapeutics market, by dugs, 2014 - 2025 (USD million)
TABLE 20 India melanoma therapeutics market, by therapy, 2014 - 2025 (USD million)
TABLE 21 India melanoma therapeutics market, by dugs, 2014 - 2025 (USD million)
TABLE 22 Latin America melanoma therapeutics market, by therapy, 2014 - 2025 (USD million)
TABLE 23 Latin America melanoma therapeutics market, by dugs, 2014 - 2025 (USD million)
TABLE 24 Brazil melanoma therapeutics market, by therapy, 2014 - 2025 (USD million)
TABLE 25 Brazil melanoma therapeutics market, by dugs, 2014 - 2025 (USD million)
TABLE 26 Mexico melanoma therapeutics market, by therapy, 2014 - 2025 (USD million)
TABLE 27 Mexico melanoma therapeutics market, by dugs, 2014 - 2025 (USD million)
TABLE 28 MEA melanoma therapeutics market, by therapy, 2014 - 2025 (USD million)
TABLE 29 MEA melanoma therapeutics market, by dugs, 2014 - 2025 (USD million)
TABLE 30 South Africa melanoma therapeutics market, by therapy, 2014 - 2025 (USD million)
TABLE 31 South Africa melanoma therapeutics market, by dugs, 2014 - 2025 (USD million)

List of Figures

FIG. 1 Market summary
FIG. 2 Market trends &outlook
FIG. 3 Market segmentation & scope
FIG. 4 Market driver relevance analysis (Current & future impact)
FIG. 5 Market restraint relevance analysis (Current & future impact)
FIG. 6 Penetration & growth prospect mapping
FIG. 7 SWOT Analysis, By Factor (political & legal, economic and technological)
FIG. 8 Porter’s Five Forces Analysis
FIG. 9 Melanoma therapeutics market therapy outlook: key takeaways
FIG. 10 Melanoma therapeutics market: Therapy movement analysis
FIG. 11 Chemotherapy market, 2014 - 2025 (USD Million)
FIG. 12 Immunotherapy market, 2014 - 2025 (USD Million)
FIG. 13 Targeted therapy market, 2014 - 2025 (USD Million)
FIG. 14 Radiation therapy market, 2014 - 2025 (USD Million)
FIG. 15 Melanoma therapeutics market drug outlook: key takeaways
FIG. 16 Melanoma therapeutics market: Drug movement analysis
FIG. 17 Branded drugs market, 2014 - 2025 (USD Million)
FIG. 18 Opdivo market, 2014 - 2025 (USD Million)
FIG. 19 Yervoy market, 2014 - 2025 (USD Million)
FIG. 20 Mekinist+Tafinlar market, 2014 - 2025 (USD Million)
FIG. 21 Keytruda market, 2014 - 2025 (USD Million)
FIG. 22 Cotellic market, 2014 - 2025 (USD Million)
FIG. 23 Zelboraf market, 2014 - 2025 (USD Million)
FIG. 24 Imlygic market, 2014 - 2025 (USD Million)
FIG. 25 Generic drugs market, 2014 - 2025 (USD Million)
FIG. 26 Regional market place: Key takeaways
FIG. 27 Regional outlook, 2016 & 2025
FIG. 28 North America melanoma therapeutics market, 2014 - 2025 (USD Million)
FIG. 29 U.S. melanoma therapeutics market, 2014 - 2025 (USD Million)
FIG. 30 Canada melanoma therapeutics market, 2014 - 2025 (USD Million)
FIG. 31 Europe melanoma therapeutics market, 2014 - 2025 (USD Million)
FIG. 32 U.K. melanoma therapeutics market, 2014 - 2025 (USD Million)
FIG. 33 Germany melanoma therapeutics market, 2014 - 2025 (USD Million)
FIG. 34 Asia Pacific melanoma therapeutics market, 2014 - 2025 (USD Million)
FIG. 35 Japan melanoma therapeutics market, 2014 - 2025 (USD Million)
FIG. 36 China melanoma therapeutics market, 2014 - 2025 (USD Million)
FIG. 37 India melanoma therapeutics market, 2014 - 2025 (USD Million)
FIG. 38 Latin America melanoma therapeutics market, 2014 - 2025 (USD Million)
FIG. 39 Brazil melanoma therapeutics market, 2014 - 2025 (USD Million)
FIG. 40 Mexico melanoma therapeutics market, 2014 - 2025 (USD Million)
FIG. 41 MEA melanoma therapeutics market, 2014 - 2025 (USD Million)
FIG. 42 South Africa melanoma therapeutics market, 2014 - 2025 (USD Million)
FIG. 43 Strategy framework
FIG. 44 Participant categorization